RxDoctor Payments DataLook up a doctor →

Selim Krim, MD

Advanced Heart Failure and Transplant Cardiology · New Orleans, LANPI 1366643025

Payments from drug & device makers

$593,777in general payments, 2019–2025

Across 322 payments — averaging $1844.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$436K
  • Endotronix, Inc.$104K
  • AstraZeneca$50K
  • Abiomed$646
  • Novartis$567
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$365
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$1,67518%
  • Travel & lodging$7108%
  • Food & beverage$6,84373%
  • Education$2032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$66,729
Medicare patients
159
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis54$1,193,427
Tyvaso DpiTreprostinil23$596,213
JardianceEmpagliflozin171$155,185
EntrestoSacubitril/Valsartan166$151,877
FarxigaDapagliflozin Propanediol116$104,075
Sirolimus113$41,834
EliquisApixaban45$41,737
Tacrolimus284$30,598
Everolimus11$11,392
Mycophenolate Mofetil109$11,253
Repatha SureclickEvolocumab20$10,780
Bumetanide182$8,190
Mycophenolic AcidMycophenolate Sodium38$7,329
BrilintaTicagrelor11$5,327
Potassium Chloride208$4,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$308$1,235,16499 claims
Boehringer IngelheimJardiance$74$155,185171 claims
NovartisEntresto$567$151,877166 claims
AstraZenecaFarxiga, Brilinta$50,300$109,402127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →